New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals can translate into registrational success.
GSK returns to Chimagen for up to $750M myeloma trispecific
Latest NewsGSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from China-based Chimagen Biosciences in a deal worth up to $750 million (€650 million), its second purchase from the company in under two years.
Agomab’s IPF drug clears first patient test
Latest NewsAgomab Therapeutics’ inhaled idiopathic pulmonary fibrosis (IPF) drug AGMB-447 showed lung-restricted exposure and inhibited its intended target in its first patient trial. The company plans to move the ALK5 inhibitor into phase 2 before the end of the year.
MaaT’s bid to overturn microbiome approval refusal suffers setback
Latest NewsMaaT Pharma has received a “negative trend” opinion in response to its request for EMA to re-examine its opposition to approving a microbiome therapy.
Axoltis ALS drug misses Phase 2 endpoint
Latest NewsFrench biotech Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the company enough encouragement to plan further development.
Cellectis scraps CAR-T pipeline in gene editing pivot
Latest NewsFrench biotech Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease.
Genfit plans Phase 2 liver failure trial after acquiring immunomodulator from Inotrem
Latest NewsFrench biotech Genfit acquired nangibotide from Inotrem in the summer and plans to start a Phase 2a trial in acute-on-chronic liver failure (ACLF) in the fourth quarter.
GSK and Roche Chinese ADC bets deliver positive phase 3 data in SCLC
Latest NewsTwo B7-H3-targeted antibody-drug conjugates licensed from Chinese biotechs have now delivered positive phase 3 survival data in relapsed small-cell lung cancer, strengthening the oncology bets GSK and Roche made in China.
BioNTech adds clinical weight to its oncology pivot at WCLC 2026
Background, Latest NewsNew data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals can translate into registrational success.
Allogenetics adds €3.8M for rejection-resistant donor lungs
Latest NewsHanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial planned for late 2027 or early 2028.
Simris steps on Heidelberg Pharma’s toes with amanitin pivot
Latest NewsSimris Group is making amanitin-based ADCs the center of its strategy under former Heidelberg Pharma CEO Andreas Pahl — less than two months after hiring the executive who helped build Heidelberg Pharma’s own amanitin platform.